Prepare Pharma & Medtech post-Covid commercial re-start

According to latest HCP and consumer surveys performed in 10 countries, Covid crisis has reduced patients visits by 45%, Rep-HCP interactions by 65%, only partially compensated by remote interactions. In order to proactively adapt to the new normal, Pharma and MedTech companies need to define precisely when to re-start, move to integrated & omnichannel customer-engagement, shift resources dynamically and adapt commercial mix to new needs and preferences #postcovid19 #commercialexcellence Continue reading